Medivir AB (publ) Stock OTC Markets
Equities
MVRBF
SE0020181014
Biotechnology & Medical Research
Sales 2024 * | 32.3M 3.09M 4.2M | Sales 2025 * | 52.05M 4.97M 6.77M | Capitalization | 362M 34.58M 47.08M |
---|---|---|---|---|---|
Net income 2024 * | -75M -7.17M -9.76M | Net income 2025 * | -92M -8.79M -11.97M | EV / Sales 2024 * | 6.11 x |
Net cash position 2024 * | 165M 15.74M 21.42M | Net cash position 2025 * | 245M 23.41M 31.87M | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 * |
-5.87
x | P/E ratio 2025 * |
-2.56
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.85% |
Latest transcript on Medivir AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Jens Lindberg
CEO | Chief Executive Officer | 53 | 22-01-23 |
Director of Finance/CFO | 50 | 19-08-11 | |
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
Director/Board Member | 68 | 18-05-02 | |
Yilmaz Mahshid
BRD | Director/Board Member | 45 | 20-05-25 |
1st Jan change | Capi. | |
---|---|---|
+14.26% | 118B | |
+13.54% | 106B | |
-2.41% | 24.28B | |
+0.67% | 21.96B | |
-9.12% | 18.16B | |
-42.12% | 16.37B | |
-17.41% | 15.56B | |
+5.48% | 13.63B | |
+30.52% | 12.27B |